Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway
Frontiers in Bioscience · 2019 · 24 (2) · 303-312
DOI: 10.2741/4719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience, 2019. Verfasst von Nan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China. Die Arbeit wurde bisher 45-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.
- Department of Oncology, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China, doxzzh@qq.com.
- Department of General Surgery,Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.
Zitieren
APA
Li, N., Zhang, Z., Jiang, G., Sun, H., & Yu, D. (2019). Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway. Frontiers in Bioscience, 24(2), 303-312. https://doi.org/10.2741/4719
Vancouver
Li N, Zhang Z, Jiang G, Sun H, Yu D. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway. Frontiers in Bioscience. 2019;24(2):303-312. doi:10.2741/4719
BibTeX
@article{Li2019,
author = {Li, Nan and Zhang, Zhenghua and Jiang, Guodan and Sun, Honglan and Yu, Deming},
title = {Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway},
journal = {Frontiers in Bioscience},
year = {2019},
volume = {24},
number = {2},
pages = {303--312},
doi = {10.2741/4719}
}
EUVIMED